NCT00120835View on ClinicalTrials.gov

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2004

Conditions
Chronic Hepatitis C
Interventions
DRUG

valopicitabine

DRUG

pegylated interferon

Trial Locations (3)

Unknown

Bradenton

San Antonio

Santurce

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00120835 - Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C | Biotech Hunter | Biotech Hunter